Improved Pathogen Detection by Fluorescence Correlation

Information

  • Research Project
  • 6791620
  • ApplicationId
    6791620
  • Core Project Number
    R43AI056766
  • Full Project Number
    1R43AI056766-01A1
  • Serial Number
    56766
  • FOA Number
    PAS-02-149
  • Sub Project Id
  • Project Start Date
    3/1/2004 - 21 years ago
  • Project End Date
    2/28/2005 - 20 years ago
  • Program Officer Name
    BEANAN, MAUREEN J.
  • Budget Start Date
    3/1/2004 - 21 years ago
  • Budget End Date
    2/28/2005 - 20 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    2/16/2004 - 21 years ago

Improved Pathogen Detection by Fluorescence Correlation

DESCRIPTION (provided by applicant): The threats posed by agents of biological warfare have gained increasing attention in light of recent global events. Many early symptoms of infection by agents of biological warfare are indistinguishable from commonly observed diseases. For this reason, rapid, diagnostic assays for early detection of infection, soon after exposure, are an essential step to speed treatment and reduce the spread of infection. Current rapid assay technologies make use of DNA purification and amplification (PCR) or the specificity of antibody detection (ELISA) and therefore require different detection instruments. In this proposal, we describe development of probe-set technology that can be used on a single FCS Diagnostic Instrument that offers rapid, specific detection of pathogens using probe-sets that target DNA, protein antigens, or both simultaneously. FCS is a single-particle detection method that measures fluctuations in fluorescence intensity in a small volume. Our preliminary studies show that we can detect a single bacterium in a small sample volume when labeled with a membrane specific probe. The focus of this proposal is to utilize FCS in a mode which crosscorrelates multiple molecular targets, both protein antigens and specific nucleic acid sequences, to effect diagnostic screens that can be used for early, and definitive diagnosis of disease. FCS offers two distinct advantages over current rapid assay technologies. First, a single instrument can be used to assay for a combination of probes. This enables diagnostic laboratories to take advantage of the best available probe targets without implementing different assay types on different instruments. The second advantage comes from crosscorrelation of multiple probes. This approach improves the probability of detecting true-positive results, and reduces the observation of false-positives. Although development of probe-sets are optimized for FCS diagnostics, the systematic approach employed and the production of specific probes can be applied to other agents of biological warfare with the same instrumentation.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    478854
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:478854\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SENSOR TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SHREWSBURY
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    015453396
  • Organization District
    UNITED STATES